Nikolas von Bubnoff
III. Medizinische Klinik und Poliklinik
Klinikum rechts der Isar
Technische Universität München
München
Germany
Name/email consistency: high
- The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro. von Bubnoff, N., Gorantla, S.P., Engh, R.A., Oliveira, T.M., Thöne, S., Aberg, E., Peschel, C., Duyster, J. Oncogene (2011)
- Chronic myelogenous leukemia: treatment and monitoring. von Bubnoff, N., Duyster, J. Dtsch. Arztebl. Int (2010)
- FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. von Bubnoff, N., Engh, R.A., Aberg, E., Sänger, J., Peschel, C., Duyster, J. Cancer Res. (2009)
- Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). von Bubnoff, N., Manley, P.W., Mestan, J., Sanger, J., Peschel, C., Duyster, J. Blood (2006)
- A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatment. von Bubnoff, N., Barwisch, S., Speicher, M.R., Peschel, C., Duyster, J. Cell. Cycle (2005)
